Vera spent $23,000 on capital expenditures in the six months ended June 30, down 94% from the comparable period. That is the filing's oddest number, because the company is not short on spending. It is short on cash generation.
Operating cash outflow nearly doubled to $206.8 million from $109.2 million a year earlier. Vera's shares rose 2.7% to $32.90 at the latest close, but the balance-sheet arithmetic is quieter: cash stood at $48.9 million, almost unchanged from $49.1 million a year ago.
The stock count supplies part of the missing context. Diluted shares rose 12.6% to 71.8 million, while financing provided $5.9 million during the six months, down from $21.8 million in the comparable period. The company did not disclose a net debt or cash figure, and the latest report does not turn the cash balance into a runway estimate.
Management attributes the heavier operating drain primarily to higher research and development and general and administrative expenses. Research and development rose 3.2% to $60.1 million, while stock compensation increased 67.5% to $15.9 million. The cash-flow section also points to the size of the operating loss and higher net operating assets and liabilities.
"Cash Flows The following table summarizes our cash flows for the periods indicated: Six Months Ended June 30, (dollars in thousands) 2026 2025 Net cash used in operating activities $ (206,753 ) $ (109,204 ) Net cash provided by (used in) investing activities (104,956 ) 43,861 Net cash provided by financing activities 5,860 21,818 Net decrease in cash and cash equivalents $ (305,849 ) $ (43,525 )"
10-Q, August 10, 2026
That table makes the tension concrete. Cutting capex did not prevent a much larger cash drain, and investing cash use also swung sharply because of license fees. This is a development-stage biotech filing, where the product pipeline is the asset being financed, not a factory being built.
The near-term operating question sits in the clinical calendar. Vera said final efficacy analysis from ORIGIN 3 is expected in the third quarter of 2026, followed by an anticipated supplemental Biologics License Application submission in the fourth quarter, with potential full FDA approval of TRUTAKNA in 2027.
"The final efficacy analysis from ORIGIN 3 is expected in the third quarter of 2026, followed by an anticipated supplemental Biologics License Application submission to the FDA expected in the fourth quarter of 2026 which could lead to potential full FDA approval of TRUTAKNA in 2027."
10-Q, August 10, 2026
That timeline identifies a specific clinical milestone, but it does not settle the funding question. Vera also warns that trial data can change as more participant data arrive and undergo audit and verification, while regulatory oversight continues.
Vera's next report should provide the next direct comparison of operating cash use, financing activity, cash and diluted shares after the ORIGIN 3 data milestone. For now, the unresolved tension is simple: Vera reported far more operating cash use while its reported cash balance is barely moving.
Vera's 10-Q pairs a six-month operating cash outflow of $206.8 million with final ORIGIN 3 efficacy analysis expected in the third quarter of 2026.